Holy Hormones Journal: According to the author of this article ” in 2003-2006 (pre-vaccine era) it was estimated that 53.1 percent of sexually active girls, aged 14-19 had HPV.” Ok red flags are flying on this one. First of all does 53.1% of the population warrant a mass vaccination program – especially when it is know that HPV passes through 90% of girls bodies without incidence in two years.
Second of all HPV pre-screening is not done prior to vaccination. The May 2006 FDA VRBPAC report clearly states that that if a girl is previously exposed to HPV, and gets vaccinated with Gardasil – the vaccine efficacy decreases by 44.6%. This could also be interpreted that her cervical cancer risk increases by that same percentage. In fact, cases of abnormal pap smears, cervical dysplasia and cervical cancer are being reported in the 9 to 26 year old demographic where historically there has been a low incidence rate. All of this is occurring post-vaccination.
Third: the low vaccine uptake needs to be explored as to why girls are not continuing the series. Up to now, the media and the medical profession have blamed parent’s and girls for the low intake – but sooner than later we must take into consideration that the girls’ might have experienced a severe reaction after the first or second shot. In fact, in the September 2008 Closing Statement on Gardasil – the FDA noted that 73.3% of girls in the clinical trials developed new medical conditions.
I am so glad that the professionals in the oncology nursing community are reading the data. It seems to me that there must be some concerns arising to so carefully scrutinize the NHANES study. It is no surprise to any of us who have been in touch with the hundreds and thousands of Gardasil girls and their families that the ‘unvaccinated’ girls fared much better.
Assessing the Overall Impact of the HPV Vaccine
The Oncology Nursing Community
A new study, published in the Journal of Infectious Diseases, provides new data regarding the effectiveness of the Human Papillomavirus (HPV) vaccine in reducing HPV prevalence.
The Advisory Committee on Immunization Practices (ACIP) started recommending routine Human Papillomavirus (HPV) vaccination in June 2006. In order to estimate the effectiveness of the HPV vaccine, researchers used data from the National Health and Nutrition Examination Surveys (NHANES), 2003-2006 and 2007-2010.
Here is the conclusion from the study: Within four years of vaccine introduction, the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake. The estimated vaccine effectiveness was high.
The study conclusion (drawn from the NHANES survey 2007-2010) was based on 740 girls, aged 14-19. However, only 358 were sexually active, and of those, only 111 had at least 1 HPV shot. If the study authors were trying to determine vaccine effectiveness, why did they include the girls who had not received a single HPV shot or did not report having sex?
An interesting fact that was not shared, was that among those 740 girls, the HPV prevalence of high-risk, non-vaccine types declined 20.7 percent (from 20.7 percent to 16.4 percent).
Table 1 from the journal article compares 1,363 girls, aged 14-19, in the pre-vaccine era (2003-2006) to all 740 girls in the post-vaccine era (2007-2010) regardless of sexual history or immunization status.
Table 3 narrows down the data to include only the sexually active girls. It then provides additional data to further compare the 111 vaccinated to the 239 unvaccinated girls (8 females without vaccination status).
In 2003-2006 (pre-vaccine era) it was estimated that 53.1 percent of sexually active girls, aged 14-19 had HPV. In 2007-2010, the overall prevalence of HPV in the same demographic declined by 19.2 percent to an overall prevalence of 42.9 percent.
Some healthcare professionals may be quick to assume that the HPV reduction was an obvious outcome after mass immunization. However, the data provided in Table 3 clearly demonstrates that the unvaccinated girls in this group had the best outcome. The study table separates the HPV prevalence into three categories: overall, vaccinated, and unvaccinated.
Australia must also caution on Gardasil, Renate Klein and Helen Lobato
Lack of Association of Guillain-Barré Syndrome With Vaccinations (Kaiser Permanente Vaccine Study Center)
Sad Story; Gardasil, Brenda Eastwood, Women’s Health Specialist